, and these changes in vascular responses may often reduce the efficacy of vasoactive drug support in septic patients. Several events have been associated with the impairment of the vascular reactivity that takes place in experimental models of septic shock, such as inactivation of norepinephrine (3), inactivation of alpha-1 adrenoceptors (4), reduction in intracellular calcium amount and sensitivity (5, 6) , increased opening of potassium channels (7) (8) (9) , and augmented activity of Na ϩ -K ϩadenosine triphosphatase pump (10) . Most of these alterations seem to be directly or indirectly (via activation of the soluble guanylate cyclase enzyme) mediated by nitric oxide (NO) (11, 12) , which is produced in large amounts during sepsis, mainly by the isoform of the inducible nitric oxide synthase (iNOS) enzyme.
Among the cell signaling pathways that are crucial to control vascular tone, the Rho-A/Rho-kinase pathway has been scarcely studied in sepsis. Rho-A is a small guanosine triphosphate-binding protein that is involved in the mediation of vascular contraction elicited by several vasoactive agents, including ␣ 1 -adrenergic agonists (13, 14) . Activation of Rho-A leads to stimulation of Rho-kinase that can phosphorylate and subsequently inactivate the myosin light chain phosphatase (15, 16) , favoring myosin light chain phosphorylation, actin-myosin interaction, and cell contraction (for review, see Ref. 17) . Inhibition of Rhokinase has been shown to reduce leukocyte adhesion in vessels (18) and liver (19) from endotoxemic mouse. Nevertheless, to our knowledge, the functionality of the Rho-A/Rho-kinase in vessels during sepsis has not been evaluated.
Thus, using first-order mesenteric arteries obtained from endotoxemic rats, we confirmed our hypothesis that a re-duction in the activity of the Rho-A/Rhokinase pathway could be involved in the impairment of vascular reactivity existing in sepsis. Considering the higher amounts of NO that are produced in sepsis and the suggested ability of this mediator to physiologically inhibit the Rho-kinase pathway in different tissues, including arteries (20, 21) , we also addressed the potential relationship between the NO/guanylate cyclase and the Rho-A/Rho-kinase pathways during endotoxemia. The results obtained support our main hypothesis revealing that although Rho-A/Rho-kinase components are up-regulated in mesenteric arteries from endotoxemic rats, its ability to inhibit the myosin phosphatase activity was markedly blunted, revealing that impairment in mechanisms involved in calcium sensitization may play a role in cardiovascular changes existing in septic shock.
MATERIALS AND METHODS
Animals. Male Wistar rats (250 -280 g) provided by Harlan Laboratories (Indianapolis, IN) were kept in our animal room under standard laboratory conditions with a constant 12hour light/dark cycle and controlled temperature (22°C Ϯ 2°C), with water and food ad libitum. All procedures were conducted in accordance with internationally accepted principles and were previously approved by the Institutional Animal Care and Use Committee from Medical College of Georgia, Augusta, GA.
Rats received a single intraperitoneal injection of lipopolysaccharide (LPS, 10 mg/kg) either 6 or 24 hours before the onset of our experiments. Control experiments were performed with animals treated with saline (vehicle to LPS; 0.1 mL/100 g).
Isolation of Small Mesenteric Arteries. Animals were killed in a saturated CO 2 chamber, and immediately the entire intestine with vascular arcades was excised and kept in cold physiologic salt solution (PSS, composition in mM: NaCl 130.3, KCl 4.7, CaCl 2 ⅐2H 2 O 1.6, KH 2 PO 4 1.18, MgSO 4 1.17, D-glucose 5.5, NaHCO 3 14.9, and EDTA 0.03). First-order branches stemming from the superior mesenteric artery were cut into 1-mm-long segments and mounted in a wire myograph (Danish Myo Technology, Denmark) for measurement of isotonic force. Preparations were exposed to a basal tension of 7.5 mN and kept under temperature controlled (37°C) and continuously aerated (5% CO 2 /95% O 2 ) 5 mL of PSS. An interval of 45 minutes with frequent changes of PSS (each 15 minutes) without addition of any drug was allowed for stabilization. After this interval, all preparations were exposed to KCl (120 mM), and the maximal contraction recorded. The vessels were washed and after a new stabilization period of 45 min-utes, the integrity of the endothelial layer was verified by the ability of acetylcholine (1 M) to relax (at least 80%) vessels contracted by phenylephrine (10 M). In the experiments shown in Figure 3 , endothelium was removed by gentle rubbing inside the vessel with a stainless-steel wire. The removal of the endothelium was confirmed by the absence of relaxation induced by acetylcholine in phenylephrine-contracted vessels.
Evaluation of the Relaxation Induced by Y-27632 and Acetylcholine. Endotheliumintact or denuded mesenteric rings obtained from LPS-treated (both groups 6 and 24 hours) or control rats were contracted with phenylephrine (30 M) and during the maintained contraction were exposed to cumulative concentrations of Y-27632 (1 nM-100 M) or acetylcholine (1 nM-1 M). In some experiments, endothelium-intact mesenteric rings obtained from control animals were incubated with the NO donor, S-nitroso-N-acetylpenicillamine (SNAP, 70 M) for 10 minutes. After this period of incubation, preparations were washed and the vasodilatory responses to Y-27632 or acetylcholine were measured 15 minutes after the removal of SNAP.
Measurement of Phenylephrine-Induced Contraction in the Absence or Presence of Y-27632. Arterial rings with functional endothelium from LPS-treated (both groups 6 and 24 hours) or control animals were incubated in the presence of Y-27632 (3 M for 10 minutes) before exposure to cumulative concentrations of phenylephrine (1 nM-300 M). Time-control experiments (without addition of Y-27632) were conducted for comparison.
Inhibition of the Nitric Oxide Synthase, Guanylate Cyclase, Cyclooxygenase, and Heme Oxygenase. In this set of experiments, endothelium-intact preparations from LPStreated (both groups 6 and 24 hours) or control animals were incubated with N -nitro-Larginine methyl ester hydrochloride (L-NAME, 100 M), indomethacin (10 M), 1400W (1 M), zinc protoporphyrin IX (500 nM), or 7-nitroindazole (7-NI, 100 M) for 40 minutes, or oxadiazolo[4,3-alpha]quinoxalin-1one (ODQ, 10 M) for 10 minutes. Each preparation was exposed to only one of these drugs. After the incubation period, the vessels were contracted with phenylephrine and the relax- Western Blotting. Protein expression was evaluated in the whole mesenteric arterial bed (except the superior mesenteric artery) taken from LPS-or saline-treated animals. In some experiments, after removal from animals the vascular bed was kept in warmed (37°C) PSS solution continuously aerated with the carbogenic mixture for 30 minutes, and then incubated with ODQ (10 M) or vehicle (dimethyl sulfoxide) for 10 minutes, followed by a single concentration of phenylephrine (30 M) for 5 minutes. After this period of incubation, tissues were quickly frozen in liquid nitrogen until they were processed in Western blot experiments. Samples containing 90 g of protein were processed for analyses of Rho-A, Rho-kinase I, Rho-kinase II, iNOS, soluble guanylate cyclase ␤1 subunit, myosin phosphatase targeting subunit 1 (MYPT1), and phosphorylated MYPT1, as previously described (22) . Immunoreactivity was detected by enhanced chemiluminescence autoradiography. The bands were quantified by densitometry using Scion Image software (Scion, Frederick, MD).
Drugs and Reagents. Phenylephrine hydrochloride, acetylcholine chloride, indomethacin, L-NAME, 7-NI, 1H-[1, 2, 4]ODQ, dimethyl sulfoxide (N-([3-(aminomethyl) phenyl]methyl)ethanimidamide dihydrochloride (1400W), zinc protoporphyrin IX, LPS (from Escherichia coli-0128:B12), sodium orthovanadate (Na 3 VO 4 ), phenylmethylsulfonyl fluoride, protease inhibitor cocktail, and all salts used to prepare the PSS were purchased from Sigma (St. Louis, MO). (R)-(ϩ)-trans-4-(1-Aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride monohydrate (Y-27632) was obtained from Tocris (Ellisville, MO). All reagents used to prepare the sodium dodecyl sulfate polyacrylamide gel electrophoresis were acquired from Bio-Rad (Hercules, CA). All primary antibodies were purchased from BD Biosciences (San Jose, CA), except antiphospho-MYPT1 that was obtained from Upstate (Lake Placid, NY), and anti-␤-actin that was obtained from Sigma. Indomethacin was dissolved in 0.5% sodium bicarbonate and ODQ was prepared in dimethyl sulfoxide. All other drugs and nutritive solutions were prepared in fresh distilled deionized water immediately before the experiments.
Statistical Analysis. Results are expressed as mean Ϯ standard error of mean of five to nine experiments. Statistical significance was determined through one-way analysis of variance followed by Bonferroni's Student's t test. A p value Ͻ0.05 was considered statistically significant. Graphs were drawn and statistical analyses were performed using GraphPad Prism version 5.01 for Windows (GraphPad Software, San Diego, CA; www.graphpad.com).
RESULTS

Enhanced Effects of Y-27632 in Small Mesenteric Arteries from LPS-Treated
Rats. The concentration-response curve for relaxation induced by Y-27632 was left shifted in small mesenteric rings from animals treated with LPS, both 6 and 24 hours before, without change in the maximal response (Fig. 1A) . The half maximal effective concentration (95% confidence intervals) was reduced from 2.10 M (1.22-3.66 M) in control to 0.21 M (0.09 -0.44 M), and 9.54 nM (0.82-110.30 nM) in LPS-treated groups 6 and 24 hours, respectively (p Ͻ 0.05). Nevertheless, the responses to acetylcholine in arteries from LPS-treated rats did not differ from control values (Fig. 1B) . Similarly, responses to Y-27632 but not to acetylcholine were increased in vessels previously exposed to SNAP, a NO donor ( Fig. 1 , C and D, respectively).
As expected, we observed reduced contractile responses to both phenylephrine ( Fig. 2A) and KCl (Fig. 2B ) in preparations obtained from endotoxemic animals. Although the incubation of Y-27632 (3 M) for 10 minutes did not cause a significant effect in phenylephrine-induced contractions in mesenteric rings from control (not treated with LPS) animals ( Fig. 2C ), this Rho-kinase inhibitor reduced the maximal response to phenylephrine by 25% and 45% in rings obtained from LPS-treated animals 6 and 24 hours before, respectively (Fig. 2 small mesenteric rings obtained from control animals ( Fig. 3A) and partially prevented the increased responses seen in preparations obtained from both 6 and 24 hours LPS-treated groups (Fig. 3, B and C, respectively). The nonselective NOS inhibitor L-NAME (100 M) also caused minor effects on Y-27632-induced relaxation in control preparations (Fig. 4A) . The incubation of L-NAME was able to normalize the relaxation induced by Y-27632 in rings obtained from animals treated with LPS 6 hours before (Fig. 4B) and caused a partial reversal in the 24hour group (Fig. 4C ). In addition, the selective inhibitor of the iNOS isoform, 1400W (1 M) did not alter the responses to Y-27632 in control preparations (Fig.  5A ) and circumvented the enhanced effects of Y-27632 at 6 hours ( Fig. 5B) , but not at 24 hours (Fig. 5C ) after LPS administration. Furthermore, although ODQ induced only a slight right shift in the effect of Y-27632 in the control group (Fig. 6A ), this soluble guanylate cyclase inhibitor completely overcame the changes in Y-27632-induced relaxation both 6 and 24 hours after LPS administration (Fig. 6, B and C, respectively) . On the other hand, exposure to 7-NI (a selective neuronal NOS inhibitor), indomethacin (a cyclooxygenase inhibitor), or zinc protoporphyrin IX (a heme oxygenase 1 inhibitor) did not alter Y-27632-induced relaxation in control or LPStreated groups (data not shown).
Changes in Protein Levels of iNOS and Rho-A/Rho-kinase Pathway in LPS-Treated Rats. Measurement of iNOS levels in the mesenteric arterial bed revealed that this enzyme is highly expressed 6 hours after LPS injection, but only small amounts are still detectable after 24 hours (Fig. 7A ). Furthermore, at least at the times investigated, we did not find differences in the amounts of soluble guanylate cyclase (sGC) protein between the LPS-treated and control groups (Fig.  7B ). Protein levels of Rho-A, ROCK-I, and ROCK-II were significantly increased in the homogenates from mesenteric arte- rial bed obtained from animals injected with LPS, both 6 and 24 hours before ( Fig. 8 ). Our Western blot analysis also revealed that the mesenteric arterial bed from LPS-treated animals presented increased levels of total MYPT1 protein ( Fig. 9A) . However, the amounts of phosphorylated MYPT1 were significantly reduced both 6 and 24 hours after induction of endotoxemia (Fig. 9B) .
Inhibition of Soluble Guanylate Cyclase Restores the Phosphorylation of MYPT1. Western blot assays revealed that incubation of the arterial mesenteric bed for 10 minutes with ODQ did not cause any significant change in the phosphor-ylation of MYPT1 in vessels from control animals. However, arteries from LPS-treated rats, both 6 and 24 hours before the experiment, presented increased amounts of phosphorylated MYPT1 after exposure to ODQ, compared with preparations incubated with vehicle only (Fig. 10 ).
DISCUSSION
The first finding of this study was that the relaxation induced by Y-27632, a selective and equipotent inhibitor of both isoforms of Rho-kinase, ROCK-I, and ROCK-II (23), is enhanced in small mesenteric arteries from LPS-treated animals, whereas acetylcholine-induced relaxation was unaltered (Fig. 1, A and B) . Similarly, previous exposure of mesenteric vessels from nonendotoxemic rats to the NO donor SNAP also increased the effects of Y-27632 but not of acetylcholine (Fig. 1, C and D) . In addition, the Rho-kinase antagonist Y-27632 was a much more potent inhibitor of contractions induced by phenylephrine in mesenteric rings from endotoxemic rats than in control (from animals not treated with LPS) preparations (Fig. 2) . Taken together, these results reinforced our hypothesis that the functionality of the Rho-A/Rho-kinase in septic shock, a condition associated with high amounts of NO, could be impaired by mechanisms involving the activity of the NO/guanylate cyclase pathway.
To investigate the role of endotheliumderived substances in the increased potency of Y-27632, we performed experiments using endothelium-denuded mesenteric rings. Our results showed that removal of endothelium was not able to normalize the relaxation induced by Y-27632, but caused a significant reduction in its potency both 6 and 24 hours after LPS (Fig. 3, B and C) , suggesting that substances derived from endothelium might be accountable for at least part of this phenomenon. Because the classic cyclooxygenase inhibitor, indomethacin, and the heme oxygenase 1 inhibitor, zinc protoporphyrin IX, did not change the effects of Y-27632 in any of our experimental groups (data not shown), the involvement of prostanoids or carbon monoxide in our findings was discarded.
The neuronal NOS inhibitor 7-NI did not influence the effects of Y-27632 (data not shown). However, incubation with L-NAME, a nonselective NOS inhibitor, as well with 1400W, an iNOS inhibitor, was able to completely restore the responses to Y-27632 at 6 hours after LPS (Figs. 4B and 5B, respectively). These results showed that, at least in this early stage of endotoxemia, the enhancement in the relaxation induced by Y-27632 is dependent on NO produced by the iNOS isoform present in both smooth muscle and endothelial cells. Importantly, enhanced production of NO mainly by iNOS has been assigned as a key event in the circulatory failure existing in septic shock (24) , but the cellular mechanisms involved are still not completely under-stood. Interestingly, NO released by iNOS seems to be crucial in the enhanced effect of Y-27632 found 6 hours but not 24 hours after LPS, because in this later stage of endotoxemia 1400W had no effect (Fig. 5C ). This lack of effect by 1400W happened at a time when the levels of iNOS found in the mesenteric arterial bed were reduced to amounts very close to that seen in control animals (Fig.  7A) . Furthermore, the ability of L-NAME (but not 1400W or 7-NI), as well as endothelium removal to partially reverse the enhanced potency of Y-27632 seen 24 hours after LPS (Figs. 3C and 4C) , suggests that endogenous NO coming from endothelial NOS isoform or sources other than iNOS (or neuronal NOS) is involved in this phenomenon at later stages of endotoxemia. Because endogenous NOS can generate superoxide anions (25) , which were associated with several damages in sepsis (26) , we are currently investigating the expression and activity of endothelial NOS, as well as the importance of superoxide generation, in our results. In addition, large amounts of NO, either exogenous or endogenous (produced by iNOS during endotoxemia), can cause long-lasting impairment in the vascular responsiveness (12, 27) . These longlasting effects of NO may be a consequence of its ability to complex with endogenous thiols, being subsequently released for long periods (28, 29) .
Despite the putative importance of the endothelium-derived hyperpolarizing factor in microcirculatory systems, such as the mesenteric bed (for review, see Ref. 30) , the ability of the NO donor SNAP to reproduce the state of hypersensitivity to Y-27632 and the full (at 6 hours) or partial (at 24 hours) reversion caused by NO synthase inhibitors suggest that the enhancement in the effects of Y-27632 seen in endotoxemic small mesenteric arteries is not dependent on EDHF.
Using the selective sGC inhibitor ODQ, we found that this enzyme plays a crucial role in the enhanced effect of Y-27632 existing in vessels from endotoxemic rats. ODQ caused a slight right shift in the effects of Y-27632 in control preparations, but was able to bring the Y-27632 response back to normal levels in those from LPS-treated rats (both groups 6 and 24 hours), as shown in Figure 6 . Several studies have investigated the role of sGC in sepsis and septic shock. Most of them demonstrated that inhibition of the sGC can ameliorate the hypotension and the hyporesponsiveness [4,3-alpha] quinoxalin-1-one (ODQ) re-establishes the phosphorylation of myosin phosphatase targeting subunit 1 (MYPT1) in vessels from endotoxemic animals. Representative Western blots and corresponding densitometric analyses (relative to ␤-actin) of phospho-MYPT1 in the whole mesenteric arterial bed (except the superior artery) from lipopolysaccharide (LPS)-treated animals (6 or 24 hours before, as indicated) or control animals (C) are shown. After removal from animals, the vessels were kept in warmed nutritive solution and were incubated with ODQ (10 M for 10 minutes) or vehicle (dimethyl sulfoxide) followed by phenylephrine (PE) (30 M for 5 minutes). After these treatments, the vessels were immediately frozen in liquid nitrogen for Western blot analyses. The data shown are the mean Ϯ SEM of four animals per group. #p value Ͻ0.05 compared with the control group and *compared with the respective time in tissue not incubated with ODQ (one-way analysis of variance followed by Student's t test subjected to Bonferroni's correction).
to vasoactive agents in experimental models of sepsis (12, (31) (32) (33) . It has been shown that the protein levels of sGC in homogenates from lungs are reduced 8 hours after the administration of LPS (34) . However, this same study (34) demonstrated that the messenger RNA for sGC is increased 24 hours after LPS. We investigated if increased protein levels of sGC in mesenteric vessels could explain the increased potency of Y-27632 described in our study. However, sGC protein levels were not different in the mesenteric bed from LPS-treated animals compared with control tissue (Fig. 7B) , showing that the importance of the cyclic guanosine monophosphate (cGMP) in the inhibition of the Rho-A/Rho-kinase pathway is not related to an increased expression of the sGC enzyme.
Because a downregulation in the Rho-A/Rho-kinase pathway components could explain the increased potency of Y-27632, we evaluated the protein levels of Rho-A and its downstream targets, ROCK-I and ROCK-II. Surprisingly, Western blot analysis revealed that Rho-A protein levels, as well as ROCK-I and ROCK-II, were significantly increased (two-or manyfolds) in vessels from LPS-treated animals ( Fig. 8) . To investigate the degree of activity of the Rho-A/Rho-kinase pathway, we also assessed the protein levels of both MYPT1 (the regulatory subunit of the smooth muscle myosin phosphatase) and phosphorylated MYPT1. The results obtained revealed that total MYPT1 protein levels (and consequently myosin phosphatase levels) were increased in the mesenteric arterial bed of endotoxemic rats (both groups 6 and 24 hours; Fig.  9A ). The MYPT1 is physiologically phosphorylated by ROCK mainly at the Thr 696 residue (35) , resulting in reduced activity of the myosin phosphatase, which favors calcium sensitization and maintenance of smooth muscle contraction (see the schematic diagram in Fig. 11 ). Thus, higher cellular amounts of myosin phosphatase could be enough to render the vascular system less responsiveness to vasoactive stimulus in septic states. However, our results also revealed that although total MYPT1 was increased, protein levels of phosphorylated MYPT1 were significantly reduced (Fig. 9B) , indicating that even with the compensatory upregulation of the Rho-A/Rho-kinase components (Rho-A, ROCK-I, and ROCK-II), this pathway was not able to properly phosphorylate and inhibit the myosin phosphatase.
Physiologic activation of sGC has been previously associated with a slight but significant inhibition of the Rho-A/Rhokinase pathway in nonendotoxemic rat aorta (21) . In our experiments, the inhibition of the soluble guanylate cyclase not only normalized the responses to Y-27632 ( Fig. 6 ) but also increased the levels of the phosphorylated MYPT1 in mesenteric arteries from LPS-treated animals ( Fig. 10 ). It has been described that 8-bromo-cGMP, an analogue of cGMP, activates the myosin phosphatase leading to calcium desensitization and vasodilation in vitro (36) and also leads to phosphorylation of Ser 852 of MYPT1, which prevents ROCK-mediated phosphorylation and inhibition of myosin phosphatase (37) .
Changes in the vascular responsiveness caused by activation of the NO/ guanylate cyclase pathway during sepsis have been frequently associated with K ϩ channels opening, among other cellular impairments (8 -12) . Our data, however, clearly reveals that the activity of the Rho-A/Rho-kinase components is suppressed by cGMP-dependent mechanisms in resistance arteries. A better understanding about the relationship between cGMP and the activity of the Rho-A/Rhokinase in septic shock may contribute to the development of new therapeutic strategies for this condition.
CONCLUSION
Severe sepsis and septic shock are still being reported worldwide as a condition associated with high mortality rates. Systemic administration of LPS in animals is an experimental model commonly used to study most of the cardiovascular changes existing during septic shock in humans. At least to our knowledge, this is the first study describing an impaired Rho-A/Rho-kinase-mediated phosphorylation of MYPT1 in the vascular smooth muscle from endotoxin-treated animals. Our results revealed that changes in cGMP-dependent mechanisms involved in calcium sensitization may play a pivotal role in the cardiovascular response to septic shock, such as the hypotension and the hyporeactivity to vasoactive drugs. 
